What question did this study set out to answer?

The aim is to evaluate the effects of targeted senotherapy using SSK1 in a mouse model of temporal lobe epilepsy (TLE).

April 15, 2026Open Access

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

Key Points

The aim is to evaluate the effects of targeted senotherapy using SSK1 in a mouse model of temporal lobe epilepsy (TLE).
Utilized a mouse model of TLE to assess treatment effects.
Employed SSK1 for targeted senotherapy compared to genetic and pharmacologic strategies.
Monitored changes in p16+ cells and spatial memory performance.
Observed a significant reduction in p16+ cells following SSK1 treatment.
Notable normalization of spatial memory in treated mice.
SSK1 demonstrated a stronger protective effect against seizures compared to other strategies.

Abstract

These findings lend further credence to the viability of targeting SCs to treat TLE. As with other genetic and pharmacologic SC ablation strategies, SSK1 produced a similar reduction in p16+ cells and normalization of spatial memory. SSK1, however, displays a stronger protective effect against seizures. In short, SSK1 is a compelling, translationally viable option for senolysis in TLE.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

David McFall

Abbas I. Hussain

Michelle Cho

Journals

Epilepsia

Actions

Institutions

Georgetown University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study